Soluble HLA revisited

Leukemia Research

Volumn 31, Issue 2, 2007, Pages 121-125

  Tabayoyong, William B ^a   Zavazava, Nicholas ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Graft monitoring; Immune modulation; Non Hodgkin's Lymphoma; Soluble human leukocyte antigen

Indexed keywords

BETA 2 MICROGLOBULIN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN;

ACUTE GRAFT REJECTION; APOPTOSIS; AUTOIMMUNE DISEASE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HLA SYSTEM; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; VIRUS INFECTION;

HLA ANTIGENS; HODGKIN DISEASE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, NON-HODGKIN; SOLUBILITY; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 33845225727     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.008     Document Type: Editorial

References (28)

1. Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. Mol Med Today 4 3 (1998) 116-121
2. Adamashvili I.M., Kelley R.E., Pressly T., and McDonald J.C. Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients. Rheumatol Int 25 (2005) 491-500
3. Rebman V., Regel J., Stolke D., and Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 13 (2003) 371-377
4. van Rood J.J., van Leeuwen A., and van Santen M. Anti HL-A2 inhibitor in normal human serum. Nature 226 (1970) 366-367
5. Charlton R.K., and Zmijewski C.M. Soluble HL-A7 antigen: localization in the β-lipoprotein fraction of human serum. Science 170 (1970) 636-637
6. Paul P., Cabestre F.A., Ibrahim E.C., et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 61 11 (2000) 1138-1149
7. Jendro M., Goronzy J.J., and Weyand C.M. Structural and functional characterization of HLA-DR molecules circulating in the serum. Autoimmunity 8 4 (1991) 289-296
8. Aultman D., Adamashvili I., Yaturu K., et al. Soluble HLA in human body fluids. Hum Immunol 60 3 (1999) 239-244
9. Zavazava N., Bottcher H., and Ruchholtz W.M. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 42 1 (1993) 20-26
10. Billing R.J., Safani M., and Peterson P. Soluble HLA antigens present in normal human serum. Tissue Antigens 10 2 (1977) 75-82
11. Pouletty P, Ferrone S, Amesland F, et al. Summary report from the first international workshop on soluble HLA antigens, Paris, August 1992. Tissue Antigens 1993;42(1):45-54.
12. Adamashvili I.M., McDonald J.C., Fraser P.A., Milford E.L., Pressly T.A., and Gelder F.B. Soluble class I HLA antigens in patients with rheumatoid arthritis and their families. J Rheumatol 22 (1995) 1025-1031
13. Tsuchiya N., Shiota M., Yamaguchi A., and Ito K. Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. Arthritis Rheum 39 5 (1996) 792-796
14. Puppo F., Pellicci R., Brenci S., et al. HLA class-I-soluble antigen serum levels in liver transplantation. A predictor marker of acute rejection. Hum Immunol 40 3 (1994) 166-170
15. Puppo F., Scudeletti M., Indiveri F., and Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response?. Immunol Today 16 (1995) 124-127
16. Aulitzky W.E., Grosse-Wilde H., Westhoff L.T., et al. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma. Clin Exp Immunol 86 (1994) 236-239
17. Shimura T., Hagihara M., Yamamoto K., et al. Quantification of serum-soluble HLA class I antigens in patients with gastric cancer. Hum Immunol 40 (1994) 183-186
18. Westhoff U., Fox C., and Otto F.J. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res 18 5B (1998) 3789-3792
19. Shimura T., Tsutsumi S., Hosouchi Y., et al. Clinical significance of soluble form of HLA class I molecule in Japanese patients with pancreatic cancer. Hum Immunol 62 (2001) 615-619
20. Nocito M., Montalban C., Gonzalez-Porque P., and Villar L.M. Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol 58 (1997) 106-111
21. Sebti Y., Le Friec G., Pangault C., et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 64 (2003) 1093-1101
22. Albitar M., Vose J.M., Johnson M.M., et al. Clinical relevance of soluble HLA-I and β2-microglobulin levels in Non-Hodgkin's Lymphoma and Hodgkin's disease. Leuk Res. 31 2 (2007) 139-145
23. Bataille R., Durie B.G., and Grenier J. Serum beta 2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 55 (1983) 439-447
24. Chronowski G.M., Wilder R.B., Tucker S.L., et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 95 (2002) 2534-2538
25. Simonsson B., Wibell L., and Nilsson K. Beta 2-microglobulin in chronic lymphocytic leukaemia. Scand J Haematol 24 (1980) 174-180
26. Zavazava N., and Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 2 9 (1996) 1005-1010
27. lck, calcium calmodulin kinase II, and calcium-independent protein kinase C signaling pathways and for NF-κB and NF-AT nuclear translocation. J Immunol 175 (2005) 7244-7254
28. Spaggiari G.M., Contini P., Dondero A., et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 100 (2002) 4098-4107